Study Title
A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Study Details
Description:
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: Y-90 (a type of radiation microsphere bead) Durvalumab (a type of immunotherapy) Gemcitabine (a type of chemotherapy) Cisplatin (a type of chemotherapy)
Sponsor:
Beth Israel Deaconess Medical Center
Contacts:
Andrea Bullock, MD, MPH (Principal Investigator)abullock@bidmc.harvard.edu
617-667-2100
Victoria Weden, BSvweden@bidmc.harvard.edu
617-667-2100
Government Study Link:
NCT05655949 - Click here to see study onClinicalTrials.gov